Osimertinib Greenlit for Some Patients with Stage 3 Lung Cancer
The EGFR inhibitor osimertinib is now available as a monotherapy for certain patients with locally advanced, unresectable non-small cell...
Progress Against Cancer
The EGFR inhibitor osimertinib is now available as a monotherapy for certain patients with locally advanced, unresectable non-small cell...
The CD38-targeted antibody was approved for patients who are ineligible for stem cell transplant. The U.S. Food and Drug...
Amivantamab with carboplatin and pemetrexed was approved for some advanced non-small cell lung cancers that progressed on or after...
Some patients with stage 2 or 3 breast cancer may now receive ribociclib with an aromatase inhibitor after surgery. ...
Pembrolizumab plus chemotherapy was approved for certain patients with untreated malignant pleural mesothelioma. The U.S. Food and Drug Administration...
The FDA approved atezolizumab and hyaluronidase-tqjs for all adult indications of intravenous atezolizumab. The U.S. Food and Drug Administration...
The FDA approved lazertinib plus amivantamab-vmjw for the treatment of certain EGFR-mutated lung cancers. The U.S. Food and Drug...
Durvalumab can now be used with chemotherapy for certain patients with resectable non-small cell lung cancer. The U.S. Food...
The FDA approved axatilimab-csfr, an inhibitor of monocytes and macrophages, for certain patients with chronic graft-versus-host disease. The U.S....
The FDA has approved vorasidenib to treat certain brain tumors harboring an IDH1 or IDH2 mutation. The U.S. Food...